BMO Capital Believes Baxter International (NYSE: BAX) Won’t Stop Here

By Carrie Williams

In a report issued on October 11, Joanne Wuensch from BMO Capital reiterated a Buy rating on Baxter International (NYSE: BAX), with a price target of $70. The company’s shares closed yesterday at $62.53, close to its 52-week high of $64.75.

According to TipRanks.com, Wuensch is a 4-star analyst with an average return of 7.4% and a 69.5% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Edwards Lifesciences.

Baxter International has an analyst consensus of Moderate Buy, with a price target consensus of $66.57.

The company has a one-year high of $64.75 and a one-year low of $43.13. Currently, Baxter International has an average volume of 2.22M.

Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. Last month, Thomas Stallkamp, a Director at BAX sold 8,920 shares for a total of $555,538.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Baxter International, Inc. provides a broad portfolio of essential renal and hospital products, including acute and chronic dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition therapies; premixed and oncolytic injectables; biosurgery products and anesthetics; drug reconstitution systems; and pharmacy automation, software and services. The company products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctor’s offices and by patients at home under physician supervision. It operates through the following segments: Hospital Products and Renal. The Hospital Products segment intravenous IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation. The Renal segment provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis, home HD, continuous renal replacement therapy and additional dialysis services. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.